Andrew is an experienced business and supply chain leader with passion for innovation, strategy, social impact and change leadership. He is currently CEO at Jamila Therapeutics. 

​

Prior to Jamila, Andrew founded the 3PG Group and PharmaStockUSA, and has also worked for Optel Group, Novartis, Pfizer, Teva and GSK in various roles where he gained multi-national experience in strategy, supply chain, innovation and sustainability in the life science industry.  

​

Andrew has a Bachelors of Science degree from Michigan State University in Material Science and Technology. Andrew currently lives with his wife and two children in Switzerland.